Publication title | First Author, year | Study acronym |
---|---|---|
Alpelisib plus fulvestrant for PIK3CA-mutated, hormone receptor-positive, human epidermal growth factor receptor-2enegative advanced breast cancer: final overall survival results from SOLAR-1 | Andre, 2021 [18] | SOLAR-1 |
Alpelisib (ALP) with fulvestrant (FUL) in patients (pts) with PIK3CA-mutated hormone receptor-positive (HR +), human epidermal growth factor receptor-2-negative (HER2-) advanced breast cancer (ABC): Primary or secondary resistance to prior endocrine therapy (ET) in the SOLAR-1 trial | Juric, 2019 [19] | SOLAR-1 |
Buparlisib plus fulvestrant versus placebo plus fulvestrant in postmenopausal, hormone receptor-positive, HER2-negative, advanced breast cancer (BELLE-2): a randomised, double-blind, placebo-controlled, phase 3 trial | Baselga, 2017[15] | BELLE-2 |
Buparlisib plus fulvestrant versus placebo plus fulvestrant for postmenopausal, hormone receptor-positive, human epidermal growth factor receptor 2-negative, advanced breast cancer: Overall survival results from BELLE-2 | Campone, 2018 [20] | BELLE-2 |
Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial | Cristofanilli, 2016[21] | PALOMA-3 |
Overall Survival with Palbociclib and Fulvestrant in Advanced Breast Cancer | Turner, 2018 [22] | PALOMA-3 |
Buparlisib plus fulvestrant in postmenopausal women with hormone-receptor-positive, HER2-negative, advanced breast cancer progressing on or after mTOR inhibition (BELLE-3): a randomised, double-blind, placebo-controlled, phase 3 trial | Di Leo, 2018 [23] | BELLE-3 |
Phase II Study of Taselisib (GDC-0032) in Combination with Fulvestrant in Patients with HER2-Negative, Hormone Receptor–Positive Advanced Breast Cancer | Dickler, 2018 [24] | |
Phase II trial of temsirolimus in patients with metastatic breast cancer | Fleming, 2012 [25] | |
Correlative Analysis of Genetic Alterations and Everolimus Benefit in Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer: Results From BOLERO-2 | Hortobagyi, 2016 [26] | BOLERO-2 |
Pictilisib for oestrogen receptor-positive, aromatase inhibitor-resistant, advanced or metastatic breast cancer (FERGI): a randomised, double-blind, placebo-controlled, phase 2 trial | Krop, 2016 [27] | FERGI |
Stand Up to Cancer Phase Ib Study of Pan-Phosphoinositide3-Kinase Inhibitor Buparlisib With Letrozole in Estrogen Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer | Mayer, 2014 [28] | |
A Phase Ib Study of Alpelisib (BYL719), a PI3Kα-specific Inhibitor, with Letrozole in ER + /HER2-Negative Metastatic Breast Cancer | Mayer, 2017 [29] | |
Correlation between PIK3CA mutations in cell-free DNA and everolimus efficacy in HR + , HER2- advanced breast cancer: results from BOLERO-2 | Moynahan, 2017 [30] | BOLERO-2 |
Natural history and outcome of patients presenting a metastatic breast cancer (mBC) with PIK3CA mutation | Mosele, 2019 [31] | SAFIR02_Breast |
Phase III study of Taselisib (GDC-0032) + fulvestrant (FULV) v FULV in patients with ER + , PIK3CA-mutant, locally advanced or metastatic breast cancer: Primary analysis from SANDPIPER | Baselga, 2018 [13] | SANDPIPER |
Clinical Significance of PIK3CA and ESR1 Mutations in Circulating Tumor DNA: Analysis from the MONARCH 2 Study of Abemaciclib plus Fulvestrant | Tolaney, 2022 [32] | MONARCH 2 |